anti-tumour activity of bisphosphonates in preclinical models of breast cancer抗肿瘤活性磷酸盐治疗乳腺癌的临床前模型中.pdfVIP

Holen and Coleman Breast Cancer Research 2010, 12:214 /content/12/6/214 R E V I E W Anti-tumour activity of bisphosphonates in preclinical models of breast cancer Ingunn Holen* and Robert E Coleman also aff ect tumour cells. h eir ability to induce apoptosis, Abstract reduce proliferation, and inhibit tumour cell migration There is increasing evidence of anti-tumour ef ects of and invasion has been demonstrated in numerous in vitro bisphosphonates from pre-clinical studies, supporting studies (reviewed in [1]). As nitrogen-containing BPs a role for these drugs beyond their traditional use in (NBPs) act by inhibiting key enzymes in the metabolic treatment of cancer-induced bone disease. A range of pathway responsible for cholesterol synthesis, which is model systems have been used to investigate the ef ects essential for all nucleated cells, the drugs do have the of dif erent bisphosphonates on tumour growth, both potential to aff ect any cell type that takes up sufficient in bone and at peripheral sites. Most of these studies quantities of them [2]. conclude that bisphosphonates cause a reduction in h e anti-tumour eff ects reported from in vitro systems tumour burden, but that early intervention and the use led to subsequent investigations using in vivo models in of high and/or repeated dosing is required. Successful diff erent tumour types, including breast cancer (reviewed eradication of cancer may only be achievable by in [3]). Most of these focussed on elucidating the eff ec